Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19206673 | 0.91 | MAPT (0.41) | MAPTCDC7SMN1; SMN2ALDH1A1PARP1 | |
| SCHEMBL492636 | 0.88 | LTB4R (0.41) | MAPTCDC7SMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL19206667 | 0.87 | LTB4R (0.39) | MAPTCDC7ADORA3ALDH1A1HTT | |
| SCHEMBL30608539 | 0.87 | CYP17A1 (0.44) | MAPTGFERMAOAADORA2BADORA3 | |
| SCHEMBL19206697 | 0.87 | MAPT (0.39) | MAPTCDC7SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17407642 | 0.86 | ALKBH3 (0.38) | MAPTCDC7MMP9MAOAMAOB | |
| SCHEMBL2680751 | 0.86 | ABCB1 (0.40) | MAPTCDC7MAOAADORA3ADORA2A | |
| SCHEMBL19206699 | 0.84 | LTB4R (0.42) | MAPTRXFP1CDC7SMN1; SMN2PKM | |
| SCHEMBL20841754 | 0.84 | CTSV (0.37) | MAPTCDC7SMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL64690 | 0.84 | ABCB1 (0.42) | CDC7MAOAADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | claimed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | claimed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | claimed |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2019-06-04 | — | — | US | claimed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | claimed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | claimed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | claimed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | disclosed |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | MAPT 2877/4885GFER 3558/4885RXFP1 4235/4885 |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | MAPT 4840/4885GFER 2590/4885RXFP1 1793/4885 |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAPT 4859/4885GFER 3428/4885RXFP1 918/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | MAPT 4863/4885GFER 2391/4885RXFP1 2107/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAPT 4859/4885GFER 3428/4885RXFP1 918/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAPT 4859/4885GFER 3428/4885RXFP1 918/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | MAPT 4840/4885GFER 2590/4885RXFP1 1793/4885 |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | MAPT 4847/4885GFER 2146/4885RXFP1 2451/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | MAPT 4849/4885GFER 2114/4885RXFP1 2571/4885 |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | MAPT 4847/4885GFER 2158/4885RXFP1 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.